An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function

Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied onl...

Full description

Bibliographic Details
Main Authors: Shyam Patel, Jennifer Andres, Kamran Qureshi
Format: Article
Language:English
Published: Hindawi Limited 2016-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2016/3191089
id doaj-6919a2c920f54da48a2502500ec662d0
record_format Article
spelling doaj-6919a2c920f54da48a2502500ec662d02020-11-24T23:39:26ZengHindawi LimitedCase Reports in Medicine1687-96271687-96352016-01-01201610.1155/2016/31910893191089An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal FunctionShyam Patel0Jennifer Andres1Kamran Qureshi2Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USADepartment of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA 19140, USADepartment of Medicine, Section of Gastroenterology, Temple University Lewis Katz School of Medicine, 3440 N. Broad Street, Philadelphia, PA 19140, USAHepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied only with rosuvastatin which shows significantly increased level of drug and is associated with increased risk of myopathy, including rhabdomyolysis. There is no mention of such HMG-CoA reductase inhibitor interaction as a class, as pravastatin did not have any clinically significant interaction with Sof/Led. Other myotoxic drugs, including colchicine are not studied. We present a case of a serious drug interaction between Sof/Led and atorvastatin, in the background of CKD and colchicine use.http://dx.doi.org/10.1155/2016/3191089
collection DOAJ
language English
format Article
sources DOAJ
author Shyam Patel
Jennifer Andres
Kamran Qureshi
spellingShingle Shyam Patel
Jennifer Andres
Kamran Qureshi
An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
Case Reports in Medicine
author_facet Shyam Patel
Jennifer Andres
Kamran Qureshi
author_sort Shyam Patel
title An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
title_short An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
title_full An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
title_fullStr An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
title_full_unstemmed An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
title_sort unexpected interaction between sofosbuvir/ledipasvir and atorvastatin and colchicine causing rhabdomyolysis in a patient with impaired renal function
publisher Hindawi Limited
series Case Reports in Medicine
issn 1687-9627
1687-9635
publishDate 2016-01-01
description Hepatitis C virus (HCV) infection affects roughly 170 million people worldwide. Sofosbuvir/Ledipasvir (Sof/Led) is a new once daily direct acting antiviral combination pill that was approved in October 2014 for use in patients with HCV genotype 1 infection. Coadministration of Sof/Led is studied only with rosuvastatin which shows significantly increased level of drug and is associated with increased risk of myopathy, including rhabdomyolysis. There is no mention of such HMG-CoA reductase inhibitor interaction as a class, as pravastatin did not have any clinically significant interaction with Sof/Led. Other myotoxic drugs, including colchicine are not studied. We present a case of a serious drug interaction between Sof/Led and atorvastatin, in the background of CKD and colchicine use.
url http://dx.doi.org/10.1155/2016/3191089
work_keys_str_mv AT shyampatel anunexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
AT jenniferandres anunexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
AT kamranqureshi anunexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
AT shyampatel unexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
AT jenniferandres unexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
AT kamranqureshi unexpectedinteractionbetweensofosbuvirledipasvirandatorvastatinandcolchicinecausingrhabdomyolysisinapatientwithimpairedrenalfunction
_version_ 1725513597119889408

Similar Items